Shanghai Hrain Biotechnology, a clinical-stage oncology immunotherapy company, raised $28 million in a Series B round led by Shenzhen Capital. Hrain is located in Shanghai’s Zhangjiang Hi-Tech Park. Founded in 2015 by returnees, the company has “one center and multiple highlights.” Its major emphasis is CAR-T products, but it also is developing other products using CAR-Natural Killer Cells, dendritic cell-based cancer vaccines. and invariant natural killer T cells. Hrain has started China clinical trials for two of its CAR-T therapies.
Source: China Biotoday
